Wellspring Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Wellspring Biosciences, Inc.
Emerging Company Profile: The US biotech is advancing a pipeline of precision medicines targeting menin and farnesyltransferase for liquid and solid tumors, respectively, building on the work of two pioneering companies in the KRAS space.
The rate of growth of the pharma pipeline slowed last year as oncology and rare diseases tightened their grip on R&D. There are also further signs of China’s rise in importance in the industry.
US FDA has issued new guidelines to providers because some patients experienced strokes or died after being treated for unruptured brain aneurysms with some neurovascular stents.
The International Stroke Conference in Los Angeles featured new data that will support an FDA submission for J&J/Cerenovous' EmboTrap revascularization device. The findings showed a high rate of "first-pass" effectiveness and EmboTrap was successful in creating final substantial reperfusion in 90% of the treated patients.
- Other Names / Subsidiaries
- Araxes Pharma LLC
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.